CVS expands drug delivery across nation

CVS Pharmacy is expanding its delivery service, CarePass, nationwide at participating pharmacy locations, the company announced.

The program, which offers prescription drug delivery for free on select drugs and other benefits for a monthly membership fee, was originally a pilot project in select markets, where CVS found broad appeal from customers. Of its CarePass audience, 20% are millennials, CVS stated.

"Initial customer response has exceeded our expectations with members utilizing the program's full benefits and becoming more engaged across all of our digital offerings,” Kevin Hourican, executive vice president, CVS Health and President, CVS Pharmacy, said in a statement.

Members of CarePass pay $5 per month, or $48 for an annual membership to receive delivery of prescription medications, access to a pharmacist helpline anytime, other special discounts on CVS Health brand items, and a monthly $10 promotional reward for in-store and online items. CarePass members also receive a free sports physical as part of their membership at their local MinuteClinic.

CVS also said it’s seeing a boost in customer purchases of about 15% to 20% from members who join the CarePass program.

The expansion of the program comes at a time when competitors from outside the industry are trying to stake a claim in the space. Amazon purchased online pharmacy PillPack last year as part of its venture into healthcare.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.